INTRODUCTION: Regulatory guidelines recommend the use of conscious, unrestrained animals for comprehensive cardiovascular safety assessment of a new therapeutic agent. Cardiovascular safety pharmacology studies normally use internal telemetry (surgical implants) in free-moving animals to monitor key ECG endpoints, like the QTc interval, but this technical approach is highly resource intensive. In toxicology studies, ECG recording is also typically performed under chemical or physical restraint, which has a number of disadvantages, e.g., anesthesia confounds, handling stress and limited data collection. External telemetry for ECG recording has the potential to overcome many of these restraint limitations, with the benefit of being a surgically non-invasive method. To evaluate this method, we used two jacket systems: Data Sciences International (DSI) JET and Integrated Telemetry Systems (ITS) PhysioJacket in implanted beagle dogs. METHODS: Heart rate and cardiac intervals were monitored continuously for 22-24 h following oral administration of vehicle (water) or 1 mg/kg E-4031. Data obtained from each jacket system was compared with implant-derived data in the same animal. RESULTS: Significant increases in QT/QTcV (25-30 ms) were noted following treatment with 1 mg/kg E-4031 in both external jacket systems and with implanted telemetry. Throughout the recording periods, the normal variations in heart rate and ECG intervals observed in conscious dogs as detected with the jacket systems, mirrored the changes observed via implant telemetry. DISCUSSION: The overall findings from this study support the use of external telemetry technology as a viable alternative to implants. The data demonstrated that jackets were sufficiently sensitive to detect QT/QTcV changes following E-4031 administration, that were comparable to those derived from implants. As such, this method is an invaluable tool for obtaining high quality ECG data from repeat-dose toxicology studies.
INTRODUCTION: Regulatory guidelines recommend the use of conscious, unrestrained animals for comprehensive cardiovascular safety assessment of a new therapeutic agent. Cardiovascular safety pharmacology studies normally use internal telemetry (surgical implants) in free-moving animals to monitor key ECG endpoints, like the QTc interval, but this technical approach is highly resource intensive. In toxicology studies, ECG recording is also typically performed under chemical or physical restraint, which has a number of disadvantages, e.g., anesthesia confounds, handling stress and limited data collection. External telemetry for ECG recording has the potential to overcome many of these restraint limitations, with the benefit of being a surgically non-invasive method. To evaluate this method, we used two jacket systems: Data Sciences International (DSI) JET and Integrated Telemetry Systems (ITS) PhysioJacket in implanted beagle dogs. METHODS: Heart rate and cardiac intervals were monitored continuously for 22-24 h following oral administration of vehicle (water) or 1 mg/kg E-4031. Data obtained from each jacket system was compared with implant-derived data in the same animal. RESULTS: Significant increases in QT/QTcV (25-30 ms) were noted following treatment with 1 mg/kg E-4031 in both external jacket systems and with implanted telemetry. Throughout the recording periods, the normal variations in heart rate and ECG intervals observed in conscious dogs as detected with the jacket systems, mirrored the changes observed via implant telemetry. DISCUSSION: The overall findings from this study support the use of external telemetry technology as a viable alternative to implants. The data demonstrated that jackets were sufficiently sensitive to detect QT/QTcV changes following E-4031 administration, that were comparable to those derived from implants. As such, this method is an invaluable tool for obtaining high quality ECG data from repeat-dose toxicology studies.
Authors: Richard E Fish; Melanie L Foster; Margaret E Gruen; Barbara L Sherman; Davidc C Dorman Journal: J Am Assoc Lab Anim Sci Date: 2017-07-01 Impact factor: 1.232
Authors: Helen Prior; Anna Bottomley; Pascal Champéroux; Jason Cordes; Eric Delpy; Noel Dybdal; Nick Edmunds; Mike Engwall; Mike Foley; Michael Hoffmann; Robert Kaiser; Ken Meecham; Stéphane Milano; Aileen Milne; Rick Nelson; Brian Roche; Jean-Pierre Valentin; Gemma Ward; Kathryn Chapman Journal: J Pharmacol Toxicol Methods Date: 2016-03-31 Impact factor: 1.950
Authors: Hugo M Vargas; Michael G Rolf; Todd A Wisialowski; William Achanzar; Anthony Bahinski; Alan Bass; Charles T Benson; Khuram W Chaudhary; Nicolas Couvreur; Corina Dota; Michael J Engwall; C Michael Foley; David Gallacher; Andrea Greiter-Wilke; Jean-Michel Guillon; Brian Guth; Herbert M Himmel; Christa Hegele-Hartung; Maki Ito; Stephen Jenkinson; Katsuyoshi Chiba; Armando Lagrutta; Paul Levesque; Eric Martel; Yoshiko Okai; Ravikumar Peri; Amy Pointon; Yusheng Qu; Ard Teisman; Martin Traebert; Takashi Yoshinaga; Gary A Gintant; Derek J Leishman; Jean-Pierre Valentin Journal: Clin Pharmacol Ther Date: 2020-09-24 Impact factor: 6.875
Authors: Naomi N Lee; Elias Salzer; Frances C Bach; Andres F Bonilla; James L Cook; Zulma Gazit; Sibylle Grad; Keita Ito; Lachlan J Smith; Andrea Vernengo; Hans-Joachim Wilke; Julie B Engiles; Marianna A Tryfonidou Journal: JOR Spine Date: 2021-06-14
Authors: Ray W Chui; Joel Baublits; Fiona A Chandra; Zack W Jones; Michael J Engwall; Hugo M Vargas Journal: Clin Transl Sci Date: 2021-07-14 Impact factor: 4.689